Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

I compared $FATE to $AFMD. $FATE currently trades

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BobDoleYahoo Member Profile
 
Followed By 52
Posts 784
Boards Moderated 0
Alias Born 07/11/17
160x600 placeholder
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019 GlobeNewswire Inc. - 6/24/2019 5:00:00 AM
Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland GlobeNewswire Inc. - 6/12/2019 5:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 4:18:14 PM
Affimed Announces Annual General Meeting of Shareholders GlobeNewswire Inc. - 6/4/2019 4:01:00 PM
Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expres... GlobeNewswire Inc. - 6/3/2019 5:00:00 AM
Affimed to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire Inc. - 5/29/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/22/2019 7:38:59 AM
Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operat... GlobeNewswire Inc. - 5/22/2019 7:30:00 AM
Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019 GlobeNewswire Inc. - 5/16/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/17/2019 4:12:05 PM
Affimed Provides Regulatory Update on AFM11 Clinical Program GlobeNewswire Inc. - 4/17/2019 4:05:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/11/2019 4:36:18 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/9/2019 7:49:11 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/5/2019 4:10:39 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/2/2019 9:20:33 AM
Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Sol... GlobeNewswire Inc. - 4/1/2019 8:00:00 AM
Affimed Reports 2018 Financial Results and Operational Progress GlobeNewswire Inc. - 3/27/2019 7:30:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/27/2019 7:03:50 AM
Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019 GlobeNewswire Inc. - 3/20/2019 5:00:00 AM
Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Hig... GlobeNewswire Inc. - 3/19/2019 5:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 9:09:09 AM
Schedule 13g Edgar (US Regulatory) - 2/12/2019 9:38:48 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/25/2019 11:33:29 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/15/2019 4:34:47 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 1/7/2019 7:03:06 AM
BobDoleYahoo   Thursday, 08/30/18 04:35:00 AM
Re: None
Post # of 85 
I compared $FATE to $AFMD. $FATE currently trades at double value w/ similar pipeline. $AFMD should be trading double $ digits. This is by far the best read. Even Zack's is wrong on the closing date. They quoted 3rd quarter 2019. It's 2018. I wrote them to let them know they made a typo. So as I and others have already noted, the $96 million + $5 billion is just part of it. Affirmed will also get additional $$ from net sales royalties.

The ABSOLUTE best part is: Genentech is willing to foot most of the R&D expense. That means less dilution & more money reimbursed. Plus since they are projected to last through 2019 with their current cash BEFORE the deal, the CEO expects the $24 million per month (which is close to what they burn per year) to extend that out much further. My guess is possibly another full year, possibly two into 2020-2021, even with ramped up R&D.

http://www.bioworld.com/content/96m-committed-affimed-shares-surge-150-potential-51b-genentech-deal-0

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist